Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07602517 · ClinicalTrials.gov registry record
Guselkumab for Overlap Inflammatory Bowel Disease and Spondyloarthritis
A clinical trial, sponsored by NYU Langone Health.
- Not yet
- Registry status
- 75
- Enrollment target
NCT07602517: Clinical Trial study, sponsored by NYU Langone Health.
NCT07602517 is a clinical trial that has not yet begun recruiting, run by NYU Langone Health. The registered enrollment target is 75 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07602517 has not yet begun recruiting, sponsored by NYU Langone Health.
- NOT YET RECRUITING
- Registry status
- 75 participants
- Enrollment target
Study Summary
This is an observational study of a prospective cohort of guselkumab-initiating Crohn's Disease (CD) and Ulcerative Colitis (UC) patients to identify new or incident spondyloarthritis. This study will include adult patients aged 18-75 with IBD who are undergoing guselkumab intravenous or subcutaneous induction over a 1-year timeframe.
Primary Outcome
BASDAI is a self-reported tool consisting of 6 questions evaluating fatigue, spinal pain, joint pain/swelling, areas of localized tenderness, and morning stiffness (duration and severity). Responses are on a 0-10 numeric rating scale; the final score is the average of responses and ranges from 0-10; higher scores indicate greater overall disease activity.
Interventions
- DRUG Guselkumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2026-05-20 |
| Est. Completion | 2029-05-20 |
What is known before NCT07602517 opens enrollment
NCT07602517 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 75 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Guselkumab is the first listed.
NCT07602517 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07602517 about?
NCT07602517 is a clinical study titled "Guselkumab for Overlap Inflammatory Bowel Disease and Spondyloarthritis". This is an observational study of a prospective cohort of guselkumab-initiating Crohn's Disease (CD) and Ulcerative Colitis (UC) patients to identify new or incident spondyloarthritis. This study will include adult patients aged 18-75 with IBD who are undergoing guselkumab intravenous or subcutaneou...
What is the current status of trial NCT07602517?
This trial is currently not yet recruiting. The enrollment target is 75 participants. The study started on 2026-05-20. Estimated completion is 2029-05-20.
What interventions are being tested in trial NCT07602517?
The interventions under investigation include: Guselkumab (DRUG).
Who is sponsoring clinical trial NCT07602517?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI